Form: 8-K

Current report filing

March 19, 2019

Exhibit 99.1

 


APOLLO MEDICAL HOLDINGS REPORTS 46% REVENUE INCREASE FOR 2018

 

 

Alhambra, CA and Glendale, CA – (PR Newswire) – March 18, 2019 – Apollo Medical Holdings, Inc. (“ApolloMed” or the “Company”) (NASDAQ: AMEH), an integrated population health management company, today announced its consolidated 2018 consolidated financial results for the year ended December 31, 2018.

 

Financial Highlights for the Year Ended December 31, 2018 compared to the Year Ended December 31, 2017:

 

  § Total revenue of $519.9 million for the year ended December 31, 2018 as compared to total revenue of $356.4 million for the year ended December 31, 2017, an increase of 46%.

 

  § Income from operations of $88.4 million for the year ended December 31, 2018 as compared to $35.1 million for the year ended December 31, 2017, an increase of 152%.

 

 

 

 

§ Net income attributable to Apollo Medical Holdings, Inc. of $10.8 million for the year ended December 31, 2018 as compared to $25.8 million for the year ended December 31, 2017, a decrease of 58%.

 

 

§ As of December 31, 2018, the Company had total assets of $513.0 million, including cash and cash equivalents of $106.9 million.

 

 

 

 

“2018 was a year of exceptional growth, and we are proud of the entire ApolloMed team,” stated Eric Chin, Chief Financial Officer of ApolloMed. “We enter 2019 with a strong foundation and good momentum and will continue to execute on our strategies for long-term success.”

 

“We made significant investments in talent and infrastructure in 2018 which impacted our near-term profitability, but which we believe positions us very well for long-term growth,” stated Warren Hosseinion, M.D., Co-Chief Executive Officer of ApolloMed. “We believe our population health management platform is central to the shift of the healthcare industry from fee-for-service payments to value-based reimbursements.”

 

“We are considering accessing the credit and equity markets this year, and deploying this capital to further accelerate our growth,” stated Thomas Lam, M.D., Co-Chief Executive Officer of ApolloMed. “Our management team has identified a pipeline of acquisitions and is actively evaluating several potential acquisitions.”

 

“National health spending, which was approximately $3.6 trillion in 2018, is projected to reach nearly $6 trillion by 2027. Approximately 10,000 people are enrolling in Medicare every day, and this is expected to continue until 2030,” stated Kenneth Sim, M.D., Executive Chairman of ApolloMed. “We believe that the Company is very well-positioned to benefit from these key economic and demographic factors. Our team is more energized than ever and we are confident in our prospects to create shareholder value through successful execution of our strategies.”

 

For more details on ApolloMed’s December 31, 2018 year end results, please refer to the Company’s Annual Report on Form 10-K to be filed with the U.S. Securities Exchange Commission (“SEC”) and accessible at www.sec.gov.

   

 

 

 

Apollo Medical Holdings, Inc.
 
Consolidated Balance Sheets (unaudited)

 

December 31,   2018     2017  
             
Assets                
                 
Current assets                
Cash and cash equivalents   $ 106,891,503     $ 99,749,199  
Restricted cash     -       18,005,661  
Investment in marketable securities     1,127,102       1,143,095  
Receivables, net     7,734,631       7,602,812  
Receivables, net – related parties     48,721,325       12,514,492  
Prepaid expenses and other current assets     8,388,231       5,144,303  
                 
Total current assets     172,862,792       144,159,562  
                 
Noncurrent assets                
Land, property and equipment, net     12,721,082       13,814,306  
Intangible assets, net     86,875,883       103,533,558  
Goodwill     185,805,880       189,847,202  
Loans receivable – related parties     17,500,000       15,000,000  
Investments in other entities – equity method     34,876,980       21,903,524  
Investment in a privately held entity that does not report net asset value per share     405,000       -  
Restricted cash – long-term     745,470       745,235  
Other assets     1,205,962       1,632,406  
                 
Total noncurrent assets     340,136,257       346,476,231  
                 
Total assets   $ 512,999,049     $ 490,635,793  

 

 

 

 

Apollo Medical Holdings, Inc.
 
Consolidated Balance Sheets (unaudited) (Continued)

 

December 31,   2018     2017  
             
Liabilities, Mezzanine Equity and Shareholders’ Equity                
                 
Current liabilities                
Lines of credit – related party   $ -     $ 5,025,000  
Accounts payable and accrued expenses     25,075,489       13,279,620  
Provider incentives payable     -       21,500,000  
Fiduciary accounts payable     1,538,598       2,017,437  
Medical liabilities     33,641,701       63,972,318  
Income taxes payable     11,621,861       3,198,495  
Bank loan, short-term     40,257       510,391  
Capital lease obligations     101,741       98,738  
                 
Total current liabilities     72,019,647       109,601,999  
                 
Noncurrent liabilities                
Lines of credit - related party     13,000,000       -  
Deferred tax liability     19,615,935       24,916,598  
Liability for unissued equity shares     1,185,025       1,185,025  
Dividend payable     -       18,000,000  
Capital lease obligations, net of current portion     517,261       619,001  
                 
Total noncurrent liabilities     34,318,221       44,720,624  
                 
Total liabilities     106,337,868       154,322,623  
                 
Commitments and Contingencies                
                 
Mezzanine equity                
Noncontrolling interest in Allied Pacific of California IPA     225,117,029       172,129,744  
                 
Shareholders’ equity                
Series A Preferred stock, par value $0.001; 5,000,000 shares authorized (inclusive of Series B Preferred stock); 1,111,111 issued and zero outstanding     -       -  
Series B Preferred stock, par value $0.001; 5,000,000 shares authorized (inclusive of Series A Preferred stock); 555,555 issued and zero outstanding     -       -  
Common stock, par value $0.001; 100,000,000 shares authorized, 34,578,040 and 32,304,876 shares outstanding, excluding 1,850,603 and 1,682,110  Treasury shares, at December 31, 2018 and 2017, respectively     34,578       32,305  
Additional paid-in capital     162,723,051       158,181,192  
Retained earnings     17,788,203       1,734,531  
      180,545,832       159,948,028  
                 
Noncontrolling interest     998,320       4,235,398  
                 
Total shareholders’ equity     181,544,152       164,183,426  
                 
Total liabilities, mezzanine equity and shareholders’ equity   $ 512,999,049     $ 490,635,793  

 

 

 

 

Apollo Medical Holdings, Inc.
 
Consolidated Statements of Income (unaudited)

 

Years ended December 31,   2018     2017  
             
Revenue                
Capitation, net   $ 344,307,058     $ 272,921,240  
Risk pool settlements and incentives     100,927,841       44,598,373  
Management fee income     49,742,755       26,983,695  
Fee-for-service, net     19,703,999       7,449,249  
Other income     5,226,099       4,403,373  
                 
Total revenue     519,907,752       356,355,930  
                 
Operating expenses                
Cost of services     361,132,111       273,453,287  
General and administrative expenses     43,353,787       26,249,532  
Depreciation and amortization     19,303,179       19,075,353  
Provision for doubtful accounts     3,887,647       -  
Impairment of goodwill and intangible assets     3,798,866       2,431,791  
                 
Total expenses     431,475,590       321,209,963  
                 
Income from operations     88,432,162       35,145,967  
                 
Other (expense) income                
Loss from equity method investments     (8,125,285 )     (1,112,541 )
Interest expense     (560,515 )     (79,689 )
Interest income     1,258,638       1,015,204  
Change in fair value of derivative instrument     -       (44,886 )
Gain on settlement of preexisting note receivable from ApolloMed     -       921,938  
Gain from investments – fair value adjustments     -       13,697,018  
Other income     1,622,131       168,102  
                 
Total other (expense) income, net     (5,805,031 )     14,565,146  
                 
Income before provision for income taxes     82,627,131       49,711,113  
                 
Provision for income taxes     22,359,640       3,886,785  
                 
Net income     60,267,491       45,824,328  
                 
Net income attributable to noncontrolling interests     49,432,489       20,022,486  
                 
Net income attributable to Apollo Medical Holdings, Inc.   $ 10,835,002     $ 25,801,842  
                 
Earnings per share – basic   $ 0.33     $ 1.01  
                 
Earnings per share – diluted   $ 0.29     $ 0.90  
                 
Weighted average shares of common stock outstanding – basic     32,893,940       25,525,786  
                 
Weighted average shares of common stock outstanding – diluted     37,914,886       28,661,735  

 

 

 

 

Note About Consolidated Entities

 

The Company consolidates entities in which it has a controlling financial interest. The Company consolidates subsidiaries in which it holds, directly or indirectly, more than 50% of the voting rights, and variable interest entities (“VIEs”) in which the Company is the primary beneficiary. Noncontrolling interests represent equity ownership interests (including certain VIEs) in the Company’s consolidated entities. The amount of net income attributable to noncontrolling interests is disclosed in the Company’s consolidated statements of income.

 

Note About Stockholders’ Equity, Certain Treasury Stock and Earnings Per Share

 

As of the date of this press release, 480,212 shares of ApolloMed’s common stock to be issued as part of the merger (the “Merger”) involving ApolloMed and Network Medical Management (“NMM”) in 2017 are subject to ApolloMed receiving from those former NMM shareholders a properly completed letter of transmittal (and related exhibits) before such former NMM shareholders may receive their pro rata portion of ApolloMed common stock and warrants. Pending such receipt, such former NMM shareholders have the right to receive, without interest, their pro rata share of dividends or distributions with a record date after the effectiveness of the Merger. The Company’s consolidated financial statements have treated such shares of common stock as outstanding, given the receipt of the letter of transmittal is considered perfunctory and the Company is legally obligated to issue these shares as of the closing of the Merger.

 

Shares of ApolloMed’s common stock owned by Allied Physicians of California IPA (d.b.a. Allied Pacific of California IPA), a VIE of the Company, are legally issued and outstanding but excluded from shares of common stock outstanding in the Company’s consolidated financial statements, as such shares are treated as treasury shares for accounting purposes. Such shares, therefore, are not included in the number of shares of common stock outstanding used to calculate the Company’s earnings per share.

 

About Apollo Medical Holdings, Inc.

 

ApolloMed is a leading physician-centric integrated population health management company, which, together with its subsidiaries, including a Next Generation Accountable Care Organization (“NGACO”), and its affiliated independent practice associations (“IPAs”) and management services organizations (“MSOs”), are working to provide coordinated, outcomes-based high-quality medical care for patients, particularly senior patients and patients with multiple chronic conditions, in a cost-effective manner.  ApolloMed focuses on addressing the healthcare needs of its patients by leveraging its integrated health management and healthcare delivery platform that includes NMM (MSO), Apollo Medical Management (MSO), ApolloMed Hospitalists, APA ACO (NGACO), Allied Physicians of California (IPA) and Apollo Care Connect (Digital Population Health Management Platform).  For more information, please visit www.apollomed.net.

 

 

 

 

Forward Looking Statements

 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, such as statements about the Company’s continued growth, ability to delivery sustainable long-term value, ability to respond to the changing environment, operational focus, strategic growth plans, and merger integration efforts. Forward-looking statements reflect current views with respect to future events and financial performance and therefore cannot be guaranteed. Such statements are based on the current expectations and certain assumptions of the Company's management, and some or all of such expectations and assumptions may not materialize or may vary significantly from actual results. Actual results may also vary materially from forward-looking statements due to risks, uncertainties and other factors, known and unknown, including the risk factors described from time to time in the Company's reports to the SEC, including without limitation the risk factors discussed in the Company's Annual Report on Form 10-K filed with the SEC on March 18, 2019.

 

FOR MORE INFORMATION, PLEASE CONTACT:

 

Warren Hosseinion, M.D.
Co-Chief Executive Officer
Apollo Medical Holdings, Inc.
(818) 839-5200
warrenhoss@apollomed.net